drugset / Trial / NCT03226574
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
NaSequentialOpen-labelTreatment
Summary
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
Timeline
- Start
- 2017-09-01
- Primary completion
- 2020-03-18
- Completion
- 2020-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiniferatoxin | Other / unclassified | 0.4 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 1 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 2 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 4 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 8 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 15 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 25 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 35 ug | Other |
Indications
No indication recorded.